Evaluation of coadministration schedules of rA1M for kidney protection after administration of 177Lu-octreotide.

IF 0.7 4区环境科学与生态学 Q4 ENVIRONMENTAL SCIENCES

Radiation protection dosimetry Pub Date : 2025-08-26 DOI:10.1093/rpd/ncaf090

Nishte Rassol, Charlotte Ytterbrink, Daniella Pettersson, Amin Al-Awar, Hana Bakr, Magnus Gram, Johan Spetz, Eva Forssell-Aronsson

{"title":"Evaluation of coadministration schedules of rA1M for kidney protection after administration of 177Lu-octreotide.","authors":"Nishte Rassol, Charlotte Ytterbrink, Daniella Pettersson, Amin Al-Awar, Hana Bakr, Magnus Gram, Johan Spetz, Eva Forssell-Aronsson","doi":"10.1093/rpd/ncaf090","DOIUrl":null,"url":null,"abstract":"<p><p>Late radiation-induced kidney toxicity limits molecular radionuclide therapy using radiopharmaceuticals such as 177Lu-octreotate and 177Lu-octreotide. Better kidney protection would allow higher amounts of radiopharmaceutical to be administered. Coadministration of recombinant human alpha-1-microglobulin (rA1M) has been suggested to protect kidneys from exposure from 177Lu-octreotate. Furthermore, early responding biomarkers are needed that identify patients that should or should not receive higher radiopharmaceutical activity. The aim of this study was to evaluate effects of different administration schedules of rA1M in combination with 177Lu-octreotide on urinary levels of retinol-binding protein 4 (RBP4) and creatinine (Cr). Mice received 60 MBq 177Lu-octreotide intravenously, plus none, one, or several rA1M injections. Urinary RBP4 and Cr concentrations were measured after 6-10 weeks. Urinary RBP4 was similar in all groups, but with large individual variations in some groups. RBP4/Cr may be a useful early-responding biomarker. Further investigations are needed to determine effects of long-term kidney protection by rA1M schedules.</p>","PeriodicalId":20795,"journal":{"name":"Radiation protection dosimetry","volume":"201 13-14","pages":"995-1005"},"PeriodicalIF":0.7000,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12392891/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiation protection dosimetry","FirstCategoryId":"93","ListUrlMain":"https://doi.org/10.1093/rpd/ncaf090","RegionNum":4,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENVIRONMENTAL SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Late radiation-induced kidney toxicity limits molecular radionuclide therapy using radiopharmaceuticals such as 177Lu-octreotate and 177Lu-octreotide. Better kidney protection would allow higher amounts of radiopharmaceutical to be administered. Coadministration of recombinant human alpha-1-microglobulin (rA1M) has been suggested to protect kidneys from exposure from 177Lu-octreotate. Furthermore, early responding biomarkers are needed that identify patients that should or should not receive higher radiopharmaceutical activity. The aim of this study was to evaluate effects of different administration schedules of rA1M in combination with 177Lu-octreotide on urinary levels of retinol-binding protein 4 (RBP4) and creatinine (Cr). Mice received 60 MBq 177Lu-octreotide intravenously, plus none, one, or several rA1M injections. Urinary RBP4 and Cr concentrations were measured after 6-10 weeks. Urinary RBP4 was similar in all groups, but with large individual variations in some groups. RBP4/Cr may be a useful early-responding biomarker. Further investigations are needed to determine effects of long-term kidney protection by rA1M schedules.

Abstract Image

查看原文本刊更多论文

177lu -奥曲肽给药后肾保护rA1M联合给药方案的评价。

晚期放射引起的肾毒性限制了使用放射性药物如177lu -奥曲酸盐和177lu -奥曲肽的分子放射性核素治疗。更好的肾脏保护将允许使用更多的放射性药物。重组人α -1微球蛋白（rA1M）被认为可以保护肾脏免受177lu - octreoate的暴露。此外，需要早期反应的生物标志物来识别应该或不应该接受更高放射性药物活性的患者。本研究的目的是评估不同给药方案rA1M联合177u -奥曲肽对尿中视黄醇结合蛋白4 （RBP4）和肌酐（Cr）水平的影响。小鼠静脉注射60mbq177lu -奥曲肽，同时不注射、一次或多次注射rA1M。6-10周后测定尿RBP4和Cr浓度。尿RBP4在所有组中相似，但在某些组中存在较大的个体差异。RBP4/Cr可能是一种有用的早期反应生物标志物。需要进一步的研究来确定rA1M方案对肾脏的长期保护作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Radiation protection dosimetry 环境科学-公共卫生、环境卫生与职业卫生

CiteScore

1.40

自引率

10.00%

发文量

223

审稿时长

6-12 weeks

期刊介绍： Radiation Protection Dosimetry covers all aspects of personal and environmental dosimetry and monitoring, for both ionising and non-ionising radiations. This includes biological aspects, physical concepts, biophysical dosimetry, external and internal personal dosimetry and monitoring, environmental and workplace monitoring, accident dosimetry, and dosimetry related to the protection of patients. Particular emphasis is placed on papers covering the fundamentals of dosimetry; units, radiation quantities and conversion factors. Papers covering archaeological dating are included only if the fundamental measurement method or technique, such as thermoluminescence, has direct application to personal dosimetry measurements. Papers covering the dosimetric aspects of radon or other naturally occurring radioactive materials and low level radiation are included. Animal experiments and ecological sample measurements are not included unless there is a significant relevant content reason.